# TABLE OF CONTENTS

In This Issue/Research Watch/News in Brief ............................................... 327

From the IASLC Tobacco Control Committee ............................................... 334

**EDITORIALS**

Reprint of “Introduction to 2021 WHO Classification of Thoracic Tumors” ....................................................................................................................... 337
Ming-Sound Tsao, MD, Andrew G. Nicholson, DM, Joseph J. Maleszewski, MD, Alexander Marx, MD, and William D. Travis, MD

Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte–Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade ........................................341
Shun Lu, PhD, MD, and Ziming Li, PhD, MD

Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer ................................................................................................... 345
Kevin ten Haaf, PhD

The Magic of ADAURA? ................................................................................... 348
D. Ross Camidge, MD, PhD

---

About the Cover: the cover image is from Figure 5 in the article by Nicholson on page 362.

---

* denotes online only article
OPEN ACCESS denotes Open Access article
TABLE OF CONTENTS (continued)

*STK11* and *KEAP1* Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues......................................................................................... 351
Rafal Dziadziszko, MD, PhD

**EDITORIAL: LUNG CANCER WORLDWIDE**

Lung Cancer in Japan........................................................................................ 353
Hidehito Horinouchi, MD, PhD, Masahiko Kusumoto, MD, PhD,
Yasushi Yatabe, MD, PhD, Keiju Aokage, MD, PhD, Shun-ichi Watanabe, MD, PhD, and Satoshi Ishikura, MD, PhD

**STATE OF THE ART: CONCISE REVIEW**

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015............................................................................................................ 362
Andrew G. Nicholson, DM, Ming S. Tsao, MD, Mary Beth Beasley, MD,
Alain C. Borczuk, MD, Elisabeth Brambilla, MD, Wendy A. Cooper, PhD,
Sanja Dacic, MD, Deepali Jain, MD, Keith M. Kerr, MD, Sylvie Lantuejoul, PhD,
Masayuki Noguchi, MD, Mauro Papotti, MD, Natasha Rekhtman, MD,
Giorgio Scagliotti, PhD, Paul van Schil, PhD, Lynette Sholl, MD, Yasushi Yatabe, PhD,
Akihiko Yoshida, PhD, and William D. Travis, MD

**ORIGINAL ARTICLES**

**Tobacco Control**

Incidence of Smoking-Related Second Primary Cancers After Lung Cancer in Germany: An Analysis of Nationwide Cancer Registry Data...................................................................................................... 388
Marian Eberl, MSc, Luana F. Tanaka, PhD, Klaus Kraywinkel, MD, and Stefanie J. Klug, MPH, PhD

**Translational Oncology**

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in *STK11*- and *KEAP1*-Mutant Lung Adenocarcinoma Is Affected by *KRAS* Mutation Status ....................................................................................... 399
Biagio Ricciuti, MD, Kathryn C. Arbour, MD, Jessica J. Lin, MD, Amir Vajdi, PhD,
Natalie Vokes, MD, Lingzhi Hong, MD, Jianjun Zhang, MD, Michael Y. Tolstorukov, PhD,
Yvonne Y. Li, PhD, Liam F. Spurr, MD, Andrew D. Cherniack, PhD,
Gonzalo Recondo, MD, PhD, Giuseppe Lamberti, MD, Xinran Wang, MS,
Deepti Venkatraman, MPH, Joao V. Alessi, MD, Victor R. Vaz, MD, Hira Rizvi, BA,
Jacklynn Egger, MD, Andrew J. Plodkowski, MD, Sara Khosrowjerdi, MD,
Subba Digumarthy, MD, Hyesun Park, MD, Nuno Vaz, MD, Mizuki Nishino, MD, MPH,
Lynette M. Sholl, MD, David Barbie, MD, Mehmet Altan, MD, John V. Heymach, MD,
Ferdinandos Skoulidis, MD, Justin F. Gainor, MD, Matthew D. Hellmann, MD, and Mark M. Awad, MD, PhD

(continued on next page)
Non-Small Cell Lung Cancers

OPEN ACCESS  Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Shun Lu, MD, PhD, Qiming Wang, MD, Guojun Zhang, MD, Xiaorong Dong, MD, Cheng-Ta Yang, MD, Yong Song, MD, Gee-Chen Chang, MD, You Lu, MD, Hongming Pan, MD, Chao-Hua Chiu, MD, Zhehai Wang, MD, Jifeng Feng, MD, Jianying Zhou, MSC, Xingxiang Xu, MD, Renhua Guo, MD, Jianhua Chen, MD, Haihua Yang, MSC, Yuan Chen, MD, Zhong Yu, MD, Her-Shyong Shiah, MD, Chin-Chou Wang, PhD, Nong Yang, MD, Jian Fang, BSc, Ping Wang, MD, Kai Wang, MD, Yanping Hu, MD, Jianxing He, MD, Ziping Wang, MD, Jianhua Shi, MSC, Shaoshui Chen, BSc, Qiong Wu, MD, PhD, Changan Sun, PhD, Chuan Li, MSC, Hongying Wei, PhD, Ying Cheng, MD, Wu-Chou Su, MD, Te-Chun Hsia, MD, Jiawei Cui, MD, Yuping Sun, MD, Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD, and James Chih-Hsin Yang, MD, PhD

OPEN ACCESS  Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Yi-Long Wu, MD, Thomas John, PhD, Christian Grohe, MD, Margarita Majem, MD, PhD, Jonathan W. Goldman, MD, Sang-We Kim, MD, PhD, Terufumi Kato, MD, Konstantin Laktionov, PhD, Huu Vinh Vu, MD, PhD, Zhijie Wang, MD, Shun Lu, MD, Kye Young Lee, MD, PhD, Charuwan Akewanlop, MD, Chong-Jen Yu, MD, PhD, Filippo de Marinis, MD, Laura Bonanno, MD, Manuel Domine, MD, PhD, Frances A. Shepherd, MD, Lingmin Zeng, PhD, Ajan Atasoy, MD, Roy S. Herbst, MD, PhD, and Masahiro Tsuboi, MD

OPEN ACCESS  CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC

Natasha B. Leighl, MD, Scott A. Laurie, MD, Glenwood D. Goss, MD, Brett G. M. Hughes, M.B.B.S., Martin Stockler, M.B.B.S., Ming-Sound Tsao, MD, David M. Hwang, MD, Phillippe Joubert, MD, Swati Kulkarni, MD, Normand Blais, MD, Anil A. Joy, MD, Mihaela Mates, MD, Punam Rana, MD, Sunil K. Yadav, MD, Craig Underhill, M.B.B.S., Christopher Lee, MD, Penelope A. Bradbury, MB, Andrea Hiltz, MSc, Janet Dancey, MD, Keyue Ding, PhD, and Francisco Vera-Badillo, MD, on behalf of the Canadian Cancer Trials Group Lung Disease Site and the Australasian Lung Cancer Trials Group

Mesothelioma

OPEN ACCESS  Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors

Farhad Kosari, PhD, Maria Disselhorst, MD, Jun Yin, PhD, Tobias Peikert, MD, Julia Udel, MA, Sarah Johnson, MS, James Smadbeck, PhD, Stephen Murphy, PhD, Alexa McCune, BS, Giannoula Karagouga, MS, Aakash Desai, MBBS, MPH, Janet Schaefer-Klein, MA, Mitesh J. Borad, MD, John Cheville, MD, George Vasmatzis, PhD, Paul Baas, MD, PhD, and Aaron S. Mansfield, MD

(continued on next page)
BRIEF REPORTS

Molecular Characterization of Peritoneal Mesotheliomas ........................................... 455
Michael Offin, MD, Soo-Ryum Yang, MD, Jacklynn Egger, BS,
Gowtham Jayakumaran, MS, Rowanne S. Spencer, MA, Jessica Lopardo, BA,
Garrett M. Nash, MD, Andrea Cereck, MD, William D. Travis, MD, Mark G. Kris, MD,
Marc Ladanyi, MD, Jennifer L. Sauter, MD, and Marjorie G. Zauderer, MD

Meningiomas in Patients With Malignant Pleural Mesothelioma
Harboring Germline BAP1 Mutations................................................................. 461
Zishuo I. Hu, MD, PhD, Markku Miettinen, MD, PhD, Martha Quezado, MD,
Alexandra P. Lebensohn, MS, CGC, Kenneth Aldape, MD, Maria Agra, RN,
Cathy Wagner, RN, Yvonne Mallory, RN, Raffit Hassan, MD, and Azam Ghafoor, MD

LETTERS TO THE EDITOR

Conceptual and Statistical Interpretation of a Systematic Review
and Meta-Analysis on Patient Adherence to Lung-RADS–Recommended
Screening Intervals in the United States .............................................................. e25
Mogana Sundari Rajagopal, PhD, Raghul Senthilnathan, BTEC, Gothandam KM, PhD,
Ravishankar Ram M, PhD, Suja Samiappan, PhD, and Rama Jayaraj, MVSc, PhD, MPH

Response to Letter to the Editor ........................................................................ e27
Yannan Lin, MD, MPH, Mingzhou Fu, MD, MPH, MHI, Kosuke Inoue, MD, PhD,
Christie Y. Jeon, ScD, and William Hsu, PhD

Clinical Thoughts on the Predictive Value of the Newly
Proposed Grading System of Invasive Pulmonary
Adenocarcinoma.................................................................................................... e28
Shenghui Li, MD, Jiajun Deng, MD, Yunlang She, MD, Likun Hou, MD, and
Chang Chen, MD, PhD

The Grading System of Lung Adenocarcinoma: Ever-Evolving
Concepts............................................................................................................. e30
Yang Zhang, MD, Chaoliang Deng, MD, Qiang Zheng, MD, Yuan Li, MD, PhD, and
Haiquan Chen, MD, PhD

Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal
Metastases From NSCLC.................................................................................... e31
Zhenyu Pan, MD, PhD

Response to Letter to the Editor Titled “Focusing on
Intrathecal Pemetrexed for Treating Leptomeningeal Metastases
from NSCLC?” ............................................................................................. e33
Chengjuan Fan, PhD, Qiuyu Zhao, MD, Chong Teng, PhD, Zhengjun Jiang, MD, and
Tao Xin, PhD
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? .............................................. e35
Roberto Ferrara, MD, Matteo Milani, Biost, Marina Chiara Garassino, MD, Mario Paolo Colombo, PhD, and Sabina Sangaletti, PhD

In Response .................................................................................................... e39
Xiuning Le, MD, PhD, and John Heymach, MD, PhD

KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: “Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously” ........................................................................................................ e40
Stefano Scalera, MSc, Marco Mazzotta, MD, Federico Cappuzzo, MD, Gennaro Ciliberto, MD, and Marcello Maugeri-Saccà, MD, PhD

Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull’s-Eye, Not Shoot in the Dark.................................................................e41
Giuseppe Pelosi, MD, MIAC